tbuckley/cabot-search huggingface dataset:
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016
Authors: Ahmed O. Elmehrath, Ahmed M. Afifi, Muneer J. Al-Husseini, Anas M. Saad, Nathaniel Wilson, Kyrillus S. Shohdy, Patrick Pilie, Mohamad Bassam Sonbol, Omar Alhalabi
Journal: JAMA Network Open (2021)

Owing to improved survival among US patients with prostate cancer (PC), patients tend to live long enough after a PC diagnosis for non-cancer-related comorbidities to be associated with their overall survival. Although studies have investigated causes of death among patients with localized PC, data are lacking regarding causes of death among patients with metastatic PC.To assess causes of death among US patients with metastatic PC from 2000 to 2016.This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results Program database to analyze a sample of 26 168 US men who received a diagnosis of metastatic PC from January 1, 2000, to December 31, 2016. Data were analyzed from February 2 to July 28, 2020.Diagnosis of metastatic PC.Standardized mortality ratios (SMRs) for different causes of death were calculated by dividing the observed number of deaths from each cause of death by the expected number of deaths in the age-matched US male population for the same period, adjusting for age and race/ethnicity.Of 26 168 patients with metastatic PC included in the analysis, 48.9% were aged 50 to 70 years (mean age at diagnosis, 70.83 years); 74.5% were White individuals, and 72.7% received a diagnosis of stage M1b metastatic PC. A total of 16 732 patients (63.9%) died during the follow-up period. The mean age at death was 74.13 years. Most deaths (59.0%) occurred within the latency period of 2 years after diagnosis of metastatic PC, whereas 31.6% occurred 2 to 5 years after diagnosis and 9.4% occurred more than 5 years after diagnosis. Of the total deaths, 13 011 (77.8%) were from PC, 924 (5.5%) were from other cancers, and 2797 (16.7%) were from noncancer causes. During all latency periods, the most common noncancer causes of death were cardiovascular diseases (SMR, 1.34; 95% CI, 1.26-1.42), chronic obstructive pulmonary disease (SMR, 1.19; 95% CI, 1.03-1.36), and cerebrovascular diseases (SMR, 1.31; 95% CI, 1.13-1.50).In this cohort study, deaths from noncancer causes, including cardiovascular disease, constituted a substantial number of deaths among men with metastatic PC. Therapy and follow-up should be tailored to the needs of each patient with metastatic PC, and counseling regarding future health risks should be provided.
P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib
Authors: J. Huynh, M. Cho, E. Kim, M. Ren, C. Amaya-Chanaga, A. Vogel
Journal: Annals of Oncology (2021)
In patients with dementia and depression, several nondrug interventions vs. usual care reduce depression symptoms
Authors: Calvin Hirsch
Journal: Annals of Internal Medicine (2021)

Source Citation Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021;372:n532. 33762262
Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction
Authors: Guillem Casas, Javier Limeres, Gerard Oristrell, Laura Gutierrez-Garcia, Daniele Andreini, Mar Borregan, Jose M. Larrañaga-Moreira, Angela Lopez-Sainz, Marta Codina-Solà, Gisela Teixido-Tura, José Antonio Sorolla-Romero, Paula Fernández-Álvarez, Josefa González-Carrillo, Andrea Guala, Lucia La Mura, Rafaela Soler-Fernández, Augusto Sao Avilés, Juan José Santos-Mateo, Josep Ramon Marsal, Aida Ribera, José Luis de la Pompa, Eduardo Villacorta, Juan Jiménez-Jáimez, Tomás Ripoll-Vera, Antoni Bayes-Genis, José Manuel Garcia-Pinilla, Julián Palomino-Doza, Coloma Tiron, Gianluca Pontone, Jan Bogaert, Giovanni D. Aquaro, Juan Ramon Gimeno-Blanes, Esther Zorio, Pablo Garcia-Pavia, Roberto Barriales-Villa, Artur Evangelista, Pier Giorgio Masci, Ignacio Ferreira-González, José F. Rodríguez-Palomares
Journal: Journal of the American College of Cardiology (2021)
Sotorasib: First Approval
Authors: Hannah A. Blair
Journal: Drugs (2021)

Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Improving the evidence on health inequities in migrant construction workers preparing for big sporting events
Authors: Andreas D Flouris, Zahra Babar, Leonidas G Ioannou, Kristine H Onarheim, Kai H Phua, Sally Hargreaves
Journal: BMJ (2021)

Data suggest migrant construction workers are at risk of work related ill health, injury, and death, but better evidence to inform policy making and improve their health is needed, say <b><i>Andreas Flouris</i></b><b><i>and colleagues</i></b>
Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: A Work Group Report of the AAAAI Allergic Skin Diseases Committee
Authors: Nives Zimmermann, J. Pablo Abonia, Stephen C. Dreskin, Cem Akin, Scott Bolton, Corinne S. Happel, Mario Geller, Désirée Larenas-Linnemann, Anil Nanda, Kathryn Peterson, Anita Wasan, Joshua Wechsler, Simin Zhang, Jonathan A. Bernstein
Journal: Journal of Allergy and Clinical Immunology (2021)
26021 Delivering care for the underserved during COVID-19 through real-time teledermatology, a cross-sectional review of patients at a student-run free clinic in Dallas
Authors: Ramiro Rodriguez, Orlando Martinez-Luna, Rebecca Vasquez
Journal: Journal of the American Academy of Dermatology (2021)

Background: Student-run free clinics (SRFCs) aid the underserved, however, the pandemic ceased our institutional SRFC operations, similar to 60-70% of SRFCs among 102 reporting institutions. Teledermatology is an attractive solution decreasing the risk of communicable disease for both patients and student volunteers during a pandemic; however, our SRFC lacked a framework. After real-time teledermatology workflow implementation, we present our experience with underserved populations. Methods: Cross-sectional review of teledermatology appointments was performed over a 10-week period. Show rate, complaints, and demographics were recorded. The R statistical analysis tool modeled the relationship between teledermatology encounter details (visit type, complaint, age, gender, primary language) and the probability of patients completing online appointments. Results: A total of 117 telehealth appointments were scheduled during the study period. Of those, 67 completed their teledermatology encounter for a teledermatology show rate of 57%. A total 134 complaints were reported: unspecified rashes/dermatitis (31%), neoplasms (26%), pigmentary disorders (18%), acneiform disorders (17%), and other (8%). Established patients (20/26 or 77%) were more likely to complete their visit compared to new patients (47/91 or 52%), P < .05. There were no differences based on age, gender, primary language, or chief complaint and completion of the teledermatology visit. Conclusion: The demand for affordable care provided by free clinics, including SRFCs, has increased during the pandemic amid job losses. In our study, just under 60% of patients completed their real-time teledermatology visit. Further studies are needed to explore whether real-time teledermatology could increase access to care in underserved populations.
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Authors: Milind Javle, Mitesh J Borad, Nilofer S Azad, Razelle Kurzrock, Ghassan K Abou-Alfa, Ben George, John Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christopher J Sweeney, Claire F Friedman, Ron Bose, David R Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard Burris
Journal: The Lancet Oncology (2021)
異なる免疫賦活遺伝子を発現する複数腫瘍崩壊HSV-1ベクターの同時の投与は、免疫抗原性の低い腫瘍モデルにおいて高い抗腫瘍効能を提供する
Authors: Ino Y, Saeki Y, Chiocca Ea, Martuza Rl, Todo T
Journal: Molecular Therapy (2003)
Using single-nucleus RNA-sequencing to interrogate transcriptomic profiles of archived human pancreatic islets
Authors: Giorgio Basile, Sevim Kahraman, Ercument Dirice, Hui Pan, Jonathan M. Dreyfuss, Rohit N. Kulkarni
Journal: Genome Medicine (2021)

Abstract Background Human pancreatic islets are a central focus of research in metabolic studies. Transcriptomics is frequently used to interrogate alterations in cultured human islet cells using single-cell RNA-sequencing (scRNA-seq). We introduce single-nucleus RNA-sequencing (snRNA-seq) as an alternative approach for investigating transplanted human islets. Methods The Nuclei EZ protocol was used to obtain nuclear preparations from fresh and frozen human islet cells. Such preparations were first used to generate snRNA-seq datasets and compared to scRNA-seq output obtained from cells from the same donor. Finally, we employed snRNA-seq to obtain the transcriptomic profile of archived human islets engrafted in immunodeficient animals. Results We observed virtually complete concordance in identifying cell types and gene proportions as well as a strong association of global and islet cell type gene signatures between scRNA-seq and snRNA-seq applied to fresh and frozen cultured or transplanted human islet samples. Conclusions We propose snRNA-seq as a reliable strategy to probe transcriptomic profiles of freshly harvested or frozen sources of transplanted human islet cells especially when scRNA-seq is not ideal.
Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
Authors: Xiang Li, Neelakshi Gohain, Si Chen, Yinghua Li, Xiaoyuan Zhao, Bo Li, William D. Tolbert, Wangxiao He, Marzena Pazgier, Honggang Hu, Wuyuan Lu
Journal: Acta Pharmaceutica Sinica B (2021)

Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.
卵円孔を介して左→右シャントを呈した,大動脈弁狭窄症合併甲状腺心の1例
Authors: 羽田健紀, 酒井龍一, 茅野千春, 渡辺秀彦, 田村泰夫, 大和真史, 北原博人
Journal: Circulation (2004)
Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19
Authors: Jordan D. Coffey, Laura A. Christopherson, Amy E. Glasgow, Kristina K. Pearson, Julie K. Brown, Shelby R. Gathje, Lindsey R. Sangaralingham, Eva M. Carmona Porquera, Abinash Virk, Robert Orenstein, Leigh L. Speicher, Dennis M. Bierle, Ravindra Ganesh, Debra L. Cox, R. Nicole Blegen, Tufia C. Haddad
Journal: npj Digital Medicine (2021)

Abstract Established technology, operational infrastructure, and nursing resources were leveraged to develop a remote patient monitoring (RPM) program for ambulatory management of patients with COVID-19. The program included two care-delivery models with different monitoring capabilities supporting variable levels of patient risk for severe illness. The primary objective of this study was to determine the feasibility and safety of a multisite RPM program for management of acute COVID-19 illness. We report an evaluation of 7074 patients served by the program across 41 US states. Among all patients, the RPM technology engagement rate was 78.9%. Rates of emergency department visit and hospitalization within 30 days of enrollment were 11.4% and 9.4%, respectively, and the 30-day mortality rate was 0.4%. A multisite RPM program for management of acute COVID-19 illness is feasible, safe, and associated with a low mortality rate. Further research and expansion of RPM programs for ambulatory management of other acute illnesses are warranted.
P80.01 A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
Authors: B. Han, J. Chen, Q. Xie, W. Yao, H. Shi, Y. Zhao, W. Song, X. Jin, Z. Wang, B. Li, Y. Xia, S. Jiao
Journal: Journal of Thoracic Oncology (2021)
Budesonide/Glycopyrronium/Formoterol: A Review in COPD
Authors: Young-A Heo
Journal: Drugs (2021)

Budesonide/glycopyrronium/formoterol (BREZTRI AEROSPHERE™; TRIXEO AEROSPHERE™) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS) budesonide, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the long-acting β
Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
Authors: Ricardo V. Cohen, Tarissa Beatrice Zanata Petry, Alexander Dimitri Miras, Cristina Mamédio Aboud, Brett Johnson, Tiago Mendonça dos Santos, Carel W. le Roux
Journal: Diabetes Care (2021)

Baseline albuminuria in patients with diabetic kidney disease (DKD) is strongly associated with progressive deterioration in kidney function (1). The remission of microalbuminuria in patients with type 2 diabetes and obesity attenuates the decline in estimated glomerular filtration rate (2). In the Microvascular Outcomes after Metabolic Surgery (MOMS) randomized controlled trial (RCT) (3), we demonstrated that the combination of best medical care and Roux-en-Y gastric bypass (RYGB) surgery is more effective in inducing remission of microalbuminuria than best medical care alone.

During the MOMS RCT, type 2 diabetes care guidelines were updated to reflect the potent renoprotective effects of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in people with DKD (4). Thus, the rate of use of the combination of these two agents (Combo) in the study was increased. In this post hoc analysis of the MOMS RCT, our objective was to determine whether the combination of two potent renoprotective medications can match the reductions of albuminuria observed after RYGB.

The MOMS RCT protocol has previously been described in detail (3). In brief, 100 patients with CKDG1–3a, A2–3, urine albumin–to–creatinine-ratio …
Sexual Harassment via Telemedicine
Authors: Alison O’Daffer
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report
Authors: Jack M Su, Lindsay B Kilburn, David B Mansur, Mark Krailo, Allen Buxton, Adesina Adekunle, Amar Gajjar, Peter C Adamson, Brenda Weigel, Elizabeth Fox, Susan M Blaney, Maryam Fouladi
Journal: Neuro-Oncology (2021)

Abstract Background A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children’s Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials. Methods Vorinostat was given once daily, Monday through Friday, during radiation therapy (54 Gy in 30 fractions), and then continued at 230 mg/m2 daily for a maximum of twelve 28-day cycles. Results Twelve patients enrolled in the phase I study; the RP2D of vorinostat given concurrently with radiation was 230 mg/m2/day, Monday through Friday weekly. The six patients enrolled at the RP2D and an additional 64 patients enrolled in the phase II study contributed to the efficacy assessment. Although vorinostat was well-tolerated, did not interrupt radiation therapy, and was permanently discontinued in only 8.6% of patients due to toxicities, risk for EFS-event was not significantly reduced compared with the target risk derived from historical COG data (P = 0.32; 1-sided). The 1-year EFS was 5.85% (95% CI 1.89–13.1%) and 1-year OS was 39.2% (27.8–50.5%). Conclusions Vorinostat given concurrently with radiation followed by vorinostat monotherapy was well tolerated in children with newly diagnosed DIPG but failed to improve outcome.
Gastrointestinal services in India during COVID-19: does governance matter? – Authors' reply
Authors: Arulraj Ramakrishnan, Aravindh Somasundaram, Sibithooran Karmegan, Paari Vijayaragavan, Ramesh Arasaradnam, Arun Palanisami, Nalla G Palanisami
Journal: The Lancet. Gastroenterology & hepatology (2021)

Sachin Sarode for their interest in our recent Correspondence. 1 As a designated COVID19 hospital (and the largest nongovernmental COVID19 hospital in our city 2 ), neither nonenforcement of government directives nor referral pattern (both before the pandemic and during it, we received less than 10% of referrals contrast, the governance bodies at private hospitals comprise medical professionals-as reported by Ramakrishnan and colleagues, 1 where the chairman is a renowned health professional.Hence, governance is perhaps a major reason for such divergent results and needs immediate attention.We would also like to bring attention to the importance of differentiating between patients who had been referred and those who presented directly to the hospital in Ramakrishnan and colleagues' report.Gastroenterology services are superspecialty facilities in India and many patients using these services are referred from private clinics.Thus, differentiation of patients into those referred and those who present directly is of vital importance.This information will indirectly reveal the active/inactive status of the surrounding small clinics, which cater to a large number of patients on a daytoday basis.
Biomarkers for Clinical Response of Extracorporeal Photopheresis
Authors: Ming Ni, Lei Wang, Angela Hückelhoven, Leopold Sellner, Jean-Marc Hoffmann, Thomas Luft, Ute Hegenbart, Stefan Schönland, Christian Kleist, Martin Sill, Bao-an Chen, Patrick Wuchter, Volker Eckstein, William Hermann Krüger, Inken Hilgendorf, Arnon Nagler, Carsten Müller-Tidow, Anthony D. Ho, Peter Dreger, Michael Schmitt, Anita Schmitt
Journal: Blood (2017)
Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era
Authors: Aaron I. Schneiderman, William J. Culpepper, Peter Rumm
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal